BAVARIAN NORDIC INFECTIOUS DISEASE RDI INNOVFIN

Projektträger – zwischengeschaltetes Finanzinstitut

BAVARIAN NORDIC A/S

Ort

• Deutschland
• Dänemark

Beschreibung

The project covers the promoter’s research activities in treatment vaccines against infectious diseases and oncology benefiting from the proprietary platform technology of viral vaccines. It covers pre-clinical and clinical trials and the main indications targeted are smallpox, Ebola and respiratory syncytial virus (RSV) for infectious diseases and prostate, colorectal and breast cancer in oncology.

Ziele

Pharmaceutical research for and clinical development of new therapeutics, including vaccines and diagnostics is one of the most costly and risky activities of knowledge creation. Through its research, development and innovation (RDI) activities, the company is expected to contribute to the competitive search for and generation of new pharmaceutical knowledge in Europe in areas that are important for the improvement of its citizens' health. In particular due to its activities in infectious diseases, it contributes to the potential prevention of future pandemics.

Sektor(en)

• Industrie

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 50 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 128 million

Umweltaspekte

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Auftragsvergabe

The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.

Projektstatus

Unterzeichnet - 12/05/2015